Major Zealand Pharma Shareholding –


Company Announcement – ​​No. 28 / 2022

Announcement of the main shareholder of Zealand Pharma: Credit Suisse Group AG, 2022

Copenhagen, DK and Boston, MA, ten June 2022 Zealand Pharma A/S (“Zealand”) (ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company specializing in the discovery and development of innovative peptide-based drugs, today announces today the receipt of a notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

Credit Suisse Group AG has notified Zealand of a change in its total ownership of shares and voting rights pursuant to Section 38 of the Capital Markets Act, and other financial instruments pursuant to Section 39 (2)(1) of the Capital Markets Act and financial instruments with similar economic effect in accordance with Article 39(2)(2) of the Capital Markets Act, so that it now holds below the threshold of 5% of the share capital and voting rights attached to Zealand shares.

Please see the attached notification form for more details.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (ZEAL) (“Zeeland”) is a biotechnology company focused on the discovery and development of peptide-based drugs. More than 10 drug candidates invented by Zealand have reached clinical development, of which two have reached the market and three candidates are in late-stage development. Zealand markets V-Go®, a basal-bolus insulin delivery option for people with diabetes, and Zegalogue®, (dasiglucagon), the first and only glucagon analogue for the treatment of severe hypoglycaemia in pediatric and adult patients with diabetes aged 6 years and older. Licensing collaborations with Boehringer Ingelheim and AstraZeneca create opportunities for more patients to potentially benefit from the experimental Zeeland-invented peptide agents currently in development.

Zealand was founded in 1998 in Copenhagen, Denmark, and has a presence across the United States, including Boston and Marlborough (MA). For more information on Zealand’s business and activities, please visit

Forward-looking statement
The above information contains forward-looking statements which provide Zealand Pharma’s expectations or forecasts regarding future events. These forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from the expectations set forth herein and may render any or all of these forward-looking statements incorrect. If any or all of these forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by these statements. All such forward-looking statements speak only as of the date of this release and are based on information available to Zealand Pharma as of the date of this release.

For more information, please contact:




Comments are closed.